Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
75,000
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
With the monetization of GenAI, here’s what we think of Alphabet’s stock
stocks
Going into earnings, Is Meta stock a buy, a sell, or fairly valued?
With a focus on leveraging its AI investments, here’s what we think of Meta stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,941.50 | 15.30 | 0.17% |
| CAC 40 | 7,738.30 | 59.92 | -0.77% |
| DAX 40 | 24,048.74 | 259.06 | -1.07% |
| Dow JONES (US) | 44,323.07 | 19.12 | -0.04% |
| FTSE 100 | 8,996.52 | 16.47 | -0.18% |
| HKSE | 25,130.03 | 135.89 | 0.54% |
| NASDAQ | 20,974.18 | 78.52 | 0.38% |
| Nikkei 225 | 39,774.92 | 44.19 | -0.11% |
| NZX 50 Index | 12,833.74 | 127.77 | -0.99% |
| S&P 500 | 6,305.60 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,677.20 | 9.00 | 0.10% |
| SSE Composite Index | 3,581.86 | 22.07 | 0.62% |